SACT Administration and Patient Care
Credit bearing module
Key facts
Course code
CPD6001
Start dates
January 2025 / January 2026
Application deadline
23 August (for a September start)
Mode of delivery
- September start: distance learning
- January start: blended learning.
Course length
Part time: Two semesters
Department
Academic level
6
Academic credits
15
More details
Delivery dates:
- Introduction day: 23/09/2024, 5.00 - 6.00pm
- Day 1: 25/09/2024, 9.30am - 4.00pm
- Day 2: 23/10/2024, 9.30am - 4.00pm
- Day 3: 13/11/2024, 9.30am - 4.00pm
- Day 4: 11/12/2024, 9.30am - 4.00pm
This course is not available to students classed as International for fees purposes.
Overview
This is a practice module designed for registered nurses who are required to administer systemic anti-cancer therapy (SACT), or in the case of uro-oncology nurses, intravesical anti-cancer treatment. It will provide you with the opportunity to develop an in-depth understanding of systemic anti-cancer treatments (SACTs). You will develop the required knowledge and skills to be able to autonomously, safely and competently administer systemic or intravesical anti-cancer therapy.
This module has been designed by professionals experienced in delivering a range of cancer care education, as well as being involved in current practice in the administration of systemic or intravesical anti-cancer therapy. The content of this course aligns with National Chemotherapy Measures (NICE 2018) and the UKONS SACT Competency Passport (2019).
How to apply
Entry requirements
You must:
- be from a respective healthcare background
- have support from the clinical manager to undertake this module of study
- have an appropriately qualified, nominated practice assessor.
Please contact the Module Leader so that you can discuss the specific practice assessment requirements.
Terms and Conditions of Enrolment
When you accept our offer, you agree to the Terms and Conditions of Enrolment. You should therefore read those conditions before accepting the offer.
Application process
Apply through our Moodle Portal.
You will need to register for the portal prior to proceeding with an application.
Tuition fees
Questions about fees?
Contact Student Finance on:
Tuition fees
Fees quoted are for the first year only. If you are studying a course that lasts longer than one year your fees will increase each year.
How and when to pay
Tuition fee instalments for the semester are due by the Monday of week 1 of each semester. Students are not liable for full fees for that semester if they leave before week 4. If the leaving date is after week 4, full fees for the semester are payable.
- For information on payment methods, please see our Make a Payment page.
- For information about refunds, please visit our Refund policy page
Financial support and scholarships
Additional costs
Please be aware that some courses will involve some additional costs that are not covered by your fees. Specific additional costs for this course are detailed below.
Learning and assessment
The teaching, learning and assessment strategy of the module reflects its student centred, patient-centred and practice-focused approach. The module has an appropriate division between structured learning activities and private study. All of the learning methods to be used will engage the student in both academic and practice learning.
You will have to undertake a period of supervised practice in the administration of systemic or intravesical anti-cancer therapy to gain competence in administering systemic or intravesical anti-cancer therapy against learning outcomes. This will be in your own place of work or a practice setting in which systemic or intravesical anti-cancer therapy is given. This will be arranged by your manager, under the supervision of an agreed practice assessor nominated by your manager who meets current national standards, such as the Cancer Measures Chemotherapy Assessor standards.
Learning and teaching
The module explores the biological mechanisms targeted by SACTs, the mechanism of action of SACT, treatment efficacy and side effects of individual drugs. It focuses on the use of stratified healthcare, based on pharmacogenomics data, and the management of treatment-related toxicities in patients receiving SACTS, illustrated by patient case studies.
The teaching sessions will incorporate the following, delivered over 4 learning units:
- Cancer biology and rationale for using SACT and intravesical anti-cancer therapy
- Pharmacology of systemic and intravesical anti-cancer therapy
- Uses of systemic and anti-cancer therapy
- Current developments: clinical trials, targeted therapies, personalised medicine
- Electronic SACT prescriptions and prescription issues
- Pre-SACT patient assessment
- The patient experience of SACT.
Programme changes:
On rare occasions we may need to make changes to our course programmes after they have been
published on the website. For more information, please visit our
changes to programmes page.